Tag Archives: group

Gene can predict aggressive prostate cancer at diagnosis — ScienceDaily

The results reported in the journal of Clinical Cancer Research, a publication of the American Association of Cancer Research, indicate the KLK3 gene — a gene on chromosome 19 responsible for encoding the prostate-specific antigen (PSA) — is not only associated with prostate cancer aggression, but a single nucleotide polymorphism (SNP) on it is more apparent in cancer patients with GS7. Researchers have linked Gleason score, an important predictor of prostate cancer outcomes, to several clinical end points, including clinical stage, cancer aggression and survival. …

Cancer during pregnancy: chemotherapy and radiotherapy are safe for babies, studies suggest

“When chemotherapy is administered after the first trimester of pregnancy, we cannot discern any problems in the children,” says lead author Dr Frederic Amant, KU Leuven and University Hospitals Leuven in Belgium. “Fear about the risks of chemotherapy administration should not be a reason to terminate a pregnancy, delay cancer treatment for the mother, or to deliver a baby prematurely.” Concerns about the potential impact of cancer treatment on unborn children has until recently left some oncologists hesitant to administer treatments to pregnant cancer patients, says Amant. To address these concerns, his group has led three new studies presented at ESMO 2014. …

Newer tests clarify hereditary risk of cancer — ScienceDaily

“There is this group of people who think they don’t need to worry about getting cancer and believe they don’t have a high family risk of getting cancer, but unfortunately do,” said Mahon, a professor in internal medicine at Saint Louis University. Mahon says her requests for genetic testing for breast cancer have more than tripled since 2013, when actress Angelina Jolie announced she had a double mastectomy because she was at genetic risk of developing breast cancer. Older genetic screenings were for the BRCA 1 and 2 genes, which are linked to the development of breast, ovarian, prostate, melanoma, pancreatic and other cancers…

Study estimates number of U.S. women potentially impacted by breast density notification legislation

Now for the first time, a new study published in the September 2014 Journal of the National Cancer Institute (JNCI) and led by Brian Sprague, Ph.D., a University of Vermont assistant professor of surgery and member of the Vermont Cancer Center, estimates the number of women in the United States for whom breast density notification legislation would potentially impact. The study was conducted with the National Breast Cancer Surveillance Consortium and utilizes data from breast cancer screening registries based at the University of Vermont, the Group Health Research Institute (Seattle, WA), the University of North Carolina, Dartmouth’s Geisel School of Medicine, the University of California-San Francisco, and the University of New Mexico. Given their findings, Sprague and his research team are asking policy makers to consider the large number of women who fall into the category of having mammographically-dense breasts in the U.S. as they debate breast density notification legislation and screening recommendations…

‘K-to-M’ Histone Mutations: How Repressing Repressors May Drive Tissue-Specific Cancers

In 2012, investigators from multiple research institutions studying the sequence of the genome from cancer patients rocked the “chromatin world” when they independently reported that mutations in the gene that encodes histone H3.3 occurred in aggressive pediatric brain tumors. This finding was stunning, as researchers had never before associated histone mutations with any disease, much less a deadly tumor…

Myc inhibition an effective therapeutic strategy against most aggressive brain tumors

In a study published last year, the group succeded in eradicating lung tumors in transgenic mice by adopting the same strategy involving the expression of Omomyc, a Myc inhibitor designed by Soucek. They also confirmed that there were no side effects post-administration of repeated and long-term treatment. Importantly, there was no evidence of resistance to therapy — one of the greatest challenges in the treatment of cancer. …

Imaging system guides brain tumor removal to improve patient outcomes

The imaging system is known as desorption electrospray ionization mass spectrometry (DESI MS). The technique was developed by R. Graham Cooks, Ph.D., at Purdue University, and the brain study was done with collaborators at Harvard Medical School and Dana Farber Cancer Institute, and is described in the June 30 issue of the Proceedings of the National Academies of Science. DESI MS promises to be a significant improvement over the current method of distinguishing brain tumor tissue from healthy tissue, which relies on an extremely lengthy and difficult procedure for surgeons and patients…